The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
about
The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The potential combination of B ...... chronic lymphocytic leukemia.
@en
The potential combination of B ...... chronic lymphocytic leukemia.
@nl
type
label
The potential combination of B ...... chronic lymphocytic leukemia.
@en
The potential combination of B ...... chronic lymphocytic leukemia.
@nl
prefLabel
The potential combination of B ...... chronic lymphocytic leukemia.
@en
The potential combination of B ...... chronic lymphocytic leukemia.
@nl
P2860
P1433
P1476
The potential combination of B ...... chronic lymphocytic leukemia.
@en
P2093
Jennifer R Brown
P2860
P304
P356
10.1080/10428194.2017.1312387
P577
2017-05-09T00:00:00Z